Mar 8, 2023 7:00 am EST Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine
Feb 24, 2023 7:00 am EST Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing
Feb 22, 2023 7:00 am EST Data Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors
Feb 9, 2023 5:00 pm EST Prospective, Multicenter Study Demonstrates That DecisionDx®-Melanoma Test Results Can Significantly Reduce the Number of Sentinel Lymph Node Biopsy (SLNB) Procedures Performed When Used Within the Context of Current Guidelines
Feb 7, 2023 5:00 pm EST Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023
Feb 1, 2023 5:00 pm EST Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year
Jan 23, 2023 7:00 am EST Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023
Jan 17, 2023 5:00 pm EST Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio
Jan 8, 2023 7:00 pm EST Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results
